Stock Analysis on Net
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Selected Financial Data
since 2005

Microsoft Excel

Paying user area

Try for free

Cytokinetics Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Statement

Cytokinetics Inc., selected items from income statement, long-term trends

US$ in thousands

Microsoft Excel
12 months ended: Revenues Operating income (loss) Net income (loss)
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Revenues (US$ in thousands):
The revenues of the company fluctuated over the years, with steady growth from 2005 to 2015, a notable peak in 2016, a decline in 2017, followed by a general upward trend until 2022.
Operating income (loss) (US$ in thousands):
The operating income trajectory shows significant variability, including large losses in some years. The company experienced a positive turn in 2009, followed by periods of losses and occasional spikes in profitability.
Net income (loss) (US$ in thousands):
The net income portrays a similar pattern to operating income, indicating a volatile financial performance with losses in several years, albeit with some years showing positive net income.

Balance Sheet: Assets

Cytokinetics Inc., selected items from assets, long-term trends

US$ in thousands

Microsoft Excel
Current assets Total assets
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Current Assets
The trend in current assets shows fluctuation over the periods, with a notable increase from 2006 to 2007 followed by a decrease in 2008. The values steadily rise from 2009 to 2017, with significant growth from 2017 to 2022.
Total Assets
Total assets experienced growth from 2005 to 2007, then a decline in 2008. There is a consistent upward trend from 2009 to 2017, with a substantial increase in values through 2022.

Balance Sheet: Liabilities and Stockholders’ Equity

Cytokinetics Inc., selected items from liabilities and stockholders’ equity, long-term trends

US$ in thousands

Microsoft Excel
Current liabilities Total liabilities Debt Stockholders’ equity (deficit)
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Current Liabilities
Current liabilities steadily increased from 2005 to 2013, then exhibited fluctuations with a substantial rise in 2020 and 2021.
Total Liabilities
Total liabilities demonstrated an upward trend throughout the period with significant growth from 2015 to 2022.
Debt
Debt showed an irregular pattern over the years, peaking in 2018 and notably increasing in 2020 and 2021.
Stockholders’ Equity (Deficit)
Stockholders’ equity swung between positive and negative values, with fluctuations seen across the years, particularly notable variations in 2017, 2018, and 2021.

Cash Flow Statement

Cytokinetics Inc., selected items from cash flow statement, long-term trends

US$ in thousands

Microsoft Excel
12 months ended: Net cash provided by (used in) operating activities Net cash (used in) provided by investing activities Net cash provided by (used in) financing activities
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Net cash provided by (used in) operating activities
The trend of net cash from operating activities shows fluctuations over the years, with negative values observed in several years. There was a substantial decrease in net cash usage in 2020 compared to previous years, but a significant negative spike in 2022.
Net cash (used in) provided by investing activities
Net cash used in investing activities was positive in some years and negative in others, indicating varying investment patterns. A noticeable negative trend is seen over the latter years, with increasing cash outflows.
Net cash provided by (used in) financing activities
Financing activities generally provided positive net cash flows, with occasional negative values. A substantial increase in cash provided by financing activities is evident in later years, particularly from 2017 onwards.

Per Share Data

Cytokinetics Inc., selected data per share, long-term trends

US$

Microsoft Excel
12 months ended: Basic earnings per share 1 Diluted earnings per share 2 Dividend per share 3
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1, 2, 3 Data adjusted for splits and stock dividends.

Basic Earnings per Share:
The trend in basic earnings per share shows considerable fluctuations over the years, with negative earnings recorded from 2005 to 2009, a sharp increase in 2009, followed by a mix of positive and negative earnings until 2022. The company experienced losses in the initial years, with improvements seen post-2009, albeit with intermittent negative values.
Diluted Earnings per Share:
Similar to basic earnings per share, diluted earnings per share exhibit a volatile pattern. Negative earnings prevailed in the early years, turning positive in 2009, and varying between negative and positive values thereafter. The trend mirrors that of basic earnings per share, indicating consistency in performance between the two metrics.
Dividend per Share:
The data for dividend per share is missing across all periods, suggesting that the company did not distribute dividends during the analyzed years. It indicates a focus on retaining earnings for internal operations or growth opportunities rather than distributing profits to shareholders.